IGF-I in experimental daunorubicin-induced cardiomyopathy in rabbits

1 The occurrence of IGF-I was investigated in rabbits with experimentally daunorubicin-induced cardiomyopathy, IGF-I was measured in the heart, serum, liver and skeletal muscle. 2 A significant increase in the IGF-I was found in the left heart ventricle in daunorubicin cardiomyopathy (152.9+/-10.0 ng/g vs 95.1+/-4.2 ng/g in the control group). This site of increased IGF-I activity corresponded well with the maximum of morphological changes (dispersed cytolysis of cardiomyocytes mostly without developed subsequent interstitial myofibrosis). 3 The highest levels of IGF-I were present in right and left cardiac atrium (but without significant differences between the groups), Furthermore, in skeletal muscle, the levels of IGF-I in the daunorubicin group (839.0+/-142.1 ng/g) were significantly higher in comparison with the control group (482.5+/-83.1 ng/g). 4 The level of IGF-I in the left ventricle in the daunorubicin group (but not in the control group) was significantly higher than that in the liver, There were no correlations observed between the levels of IGF-I in the heart and in the serum. 5 The increase in TGF-I concentrations in the left heart ventricle after the administration of daunorubicin may thus reflect possible autocrine/paracrine role of IGF-I in cardiomyopathy.